Inhibitors of adenosine deaminase
References (174)
- et al.
Effects of adenosine and adenine nucleotides on adenosine 5′-diphosphate induced rat platelet aggregation
Biochem. Pharmac.
(1980) - et al.
Adenosine analogs and human platelets. Effects on nucleotide pools and the aggregation phenomenon
Biochem. Pharmac.
(1975) In vivo inhibition of adenosine deaminase by 2′-deoxycoformycin in mouse blood and leukemia L1210 cells
Biochem. Pharmac.
(1980)- et al.
Coformycin and deoxycoformycin: Tight binding inhibitors of adenosine deaminase
- et al.
A possible association between the nucleoside transport system of human erythrocytes and adenosine deaminase
Biochem. Pharmac.
(1975) - et al.
Potent inhibition of muscle 5′-AMP deaminase by nucleoside antibiotics coformycin and deoxycoformycin
Biochem. Pharmac.
(1977) - et al.
Adenosine deaminase from human erythrocytes
Meth. Enzymol.
(1978) - et al.
Adenosine deaminase from human erythrocytes: Purification and effects of adenosine analogs
Biochem. Pharmac.
(1975) - et al.
Tight-binding inhibitors IV. Inhibition of adenosine deaminases by various inhibitors
Biochem. Pharmac.
(1977) - et al.
Multiforms of human adenosine deaminase: I. Purification and characterization of two molecular forms
Biochim. biophys. Acta
(1972)
Identification of the bioactive enantiomer of erythro-3-(adenin-9-yl)-2-nonanol (EHNA). A semitight binding inhibitor of adenosine deaminase
Biochem. Pharmac.
The biosynthesis of thymidylic acid IV. Further studies on thymidylate synthetase
J. biol. Chem.
Studies of purine in mouse leukemia
Biochem. Pharmac.
Inhibition by nitrobenzylthioinosine of uptake of adenosine. 2′-deoxyadenosine and 9-β-d-arabinofuranosyladenine by human and mouse erythrocytes
Biochem. Pharmac.
Nitrobenzylthioinosine binding sites in the erythrocyte membrane
Biochim. biophys. Acta
Tight binding inhibitors: I. Kinetic behavior
Biochem. Pharmac.
Tight-binding inhibitors: III. A new approach for the determination of competition between tight-binding inhibitors and substrates—inhibition of adenosine deaminase by coformycin
Biochem. Pharmac.
Tight-binding inhibitors: II. Non-steady state nature of inhibition of milk xanthine oxidase by allopurinol and alloxanthine and of human erythrocytic adenosine deaminase by coformycin
Biochem. Pharmac.
Enzyme inhibition titration assay for 2′-deoxycoformycin and its application to the study of the relationship between drug concentration and tissue adenosine deaminase in dogs and rats
Biochem. Pharmac.
The formation of deoxyadenosine phosphate in ascites tumor cells in vitro and its effect on deoxyribonucleic acid synthesis
Biochim. biophys. Acta
Adenosine deaminase inhibitors: Differential effects on multiple forms of adenosine deaminase
Biochem. biophys. Res. Commun.
Human adenosine deaminase: Purification and subunit structure
J. biol. Chem.
Adenylate deaminase: Potent inhibition by 2′-deoxycoformycin 5′-phosphate
Biochem. biophys. Res. Commun.
Adenosine deaminase deficiency in two patients with severely impaired cellular immunity
Lancet
The effects of 2′-deoxycoformycin on the action of cordycepin on nuclear RNA synthesis in regenerating liver
Toxicol. appl. Pharmac.
Cordycepin and xylosyladenine: Inhibitors of methylation of nuclear RNA
Biochem. biophys. Res. Commun.
Evidence that xylosyladenine affects methylation by inhibition of synthesis
Cancer Lett.
Adenosine metabolism in cultured lymphoid cells
Adv. Enzyme Regul.
Specificity of adenosine deaminase inhibitors
Biochem. Pharmac.
Enhancement of the biological activity of cordycepin (3′-deoxyadenosine) by the adenosine deaminase inhibitor 2′-deoxycoformycin
Biochem. Pharmac.
Successful fetal liver transplantation in a child with severe combined immunodeficiency
Lancet
Inhibition of human T-cell rosette formation by the adenosine deaminase inhibitor erythro-9-(2-hydroxy-3-nonyl) adenine hydrochloride (EHNA)
Clin. Immunol. Immunopath.
Clinical pharmacology of deoxycoformycin
Blood
Enzyme inhibition in relation to chemotherapy
Some aspects of the pharmacology of the adenosine deaminase inhibitors 2′-deoxycoformycin and erythro-9-(2-hydroxy-3-nonyl)adenine
Enhancement of the biological activity of adenosine analogs by the adenosine deaminase inhibitor 2′-deoxycoformycin
Pharmacology
Recovery of 2′-deoxycoformycin-inhibited adenosine deaminase of mouse erythrocytes and leukemia L1210 in vivo
Cancer Res.
Recovery of deoxycoformycin (DCF) inhibited adenosine deaminase (ADA) of mouse tissues
Pharmacologist
Deoxycoformycin toxicity in mice after long term treatment
Cancer Chemother. Pharmac.
Purine nucleoside metabolism in the erythrocytes of patients with adenosine deaminase deficiency and severe combined immunodeficiency
J. clin. Invest.
Role of the cell membrane in the interaction of adenosine deaminase and deoxycoformycin
The control of the metabolism and the hormonal role of adenosine
Essays Biochem.
On the mechanism of adenosine deaminase action
Biochem. biophys. Res. Commun.
Physiological and Regulatory Functions of Adenosine and Adenine Nucleotides
Inhibition of maturation of human percursor lymphocytes by coformycin, inhibitor of the enzyme adenosine deaminase
J. exp. Med.
Adenosine deaminase inhibitors. The conversion of a single chiral synthon into erythro- and threo-9-(2-hydroxy-3-nonyl)adenine
J. med. Chem.
Phase I and biochemical pharmacological studies of deoxycoformycin
Effect of chirality in erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA) on adenosine deaminase inhibition
Biochem. Pharmac.
Inhibition of adenosine deaminase by co-vidarabine and its effect on the metabolic disposition of adenine arabinoside (vidarabine)
Ann. N.Y. Acad. Sci.
Metabolic effects of 9-β-d-arabinosyladenines in ascites tumor cells
Cancer Res.
Cited by (104)
Modifications of flexible nonyl chain and nucleobase head group of (+)-erythro-9-(2′s-hydroxy-3′s-nonyl)adenine [(+)-EHNA] as adenosine deaminase inhibitors
2017, Bioorganic and Medicinal ChemistryCitation Excerpt :The desired analogues were synthesized using intermediate 5a and 5b as described in Scheme 6. In two steps 3-hydroxy group of 5a/5b was converted to mesylate and displacement by SN2 reaction with 4-imidazolecarboxamide in the presence of NaH in DMF afforded 25a-b.28 Whereas 25c-f were synthesized by reacting 4-Diboc-aminopyrazolo[3,4-d]pyrimidine25a/4-chloro-7H-pyrrolo[2,3-d]pyrimidine and 5a/5b under Mitsunobu condition, Finally deprotection of 25a-f afforded desired compounds 26a-f. We probed the role of C-2′ hydroxyl and chirality on potency (P3 segment modification, Fig. 2) by converting secondary hydroxyl of 7b to ketone 29 and tertiary hydroxyl group 31.
Dose finding of 3'deoxyadenosine and deoxycoformycin for the treatment of Trypanosoma evansi infection: An effective and nontoxic dose
2015, Microbial PathogenesisCitation Excerpt :Mechanistically, as an adenosine analogue, Cordycepin most likely replaces the ribose of adenosine and consequently interrupts nucleolar RNA synthesis [15–17]. On the other hand, Pentostatin is a deoxyadenosine analogue and a potent inhibitor of E-ADA, an enzyme of purine metabolism [18]. Blockade of E-ADA leads to the accumulation of cytotoxic de-oxyadenosine triphosphate metabolites in the cell, inhibition of DNA synthesis and eventual cell death [19,20].
Functional nucleic acid entrapment in sol-gel derived materials
2013, MethodsCitation Excerpt :Each final material, single-phase or top layer, is allowed to gel and age for 2 h prior to addition of the buffer overlay. Assays are performed by first adding 15 different concentrations of EHNA (one per well), spanning the expected IC50 value of 100 nM (derived from literature KI of 6.5 nM [51]), to the buffer overlay and incubating for 60 min. Following inhibitor incubation, 1 mM final concentration of adenosine is added and the fluorescence monitored over time as in experiments listed above.